Dr. med. Daniel Sasca
internal medicine, hematology, oncology, and drug-based tumor therapy
internal medicine, hematology, oncology, and drug-based tumor therapy
Overview
Country, City
Germany, Mainz
Health facility
University Hospital Johannes Gutenberg Mainz
Medical unit
Department of hematology and medical oncology
About the doctor
Skills & Expertise
leukemia
oncology
hematology
myeloid leukemia
tumor
drug resistance
tumor therapy
gene expression
internal medicine
drugbased tumor therapy
npm1 mutation
mutational synergy
chromatin regulation
myeloid neoplasms
stem cell
matrixassociated protein safb
venetoclax
cd56
ziftomenib
mutation
neoplasms
ncam1
expression flt3itd
deregulation interferon signal
disturbed erythropoiesis
p53 activation
lymphoid progenitors
flt3 mutations
myelogenous leukemias
mutant variants
kras mutant
monocytic cells
metabolic dependency
znf217 mutations
hairycell leukemia
hoxa9 forms
urologic oncology
cell lymphoma
myeloid malignancies
hairycell
trem1
glutaminolysis
lymphoid
sirt1
neutrophils
erythropoiesis
malignancies
interferon
lymphoma
chemotherapy
Resume
CV (Curriculum Vitae)
Education
- Studied human medicine
- Obtaining a license for medical practice
- Defense of the dissertation
- Obtaining specialization in internal medicine
- Habilitation and a teaching license
- Received additional qualifications in the field of hematology, oncology, and drug-based tumor therapy
- 2015-2017 Postdoctoral Fellow at the University of Cambridge, Stem Cell Institute
Experience
- 2008-2017 Senior Physician of the Department of hematology and medical oncology at the University Hospital Johannes Gutenberg Mainz
- 2018 Head of the Department of hematology and medical oncology at the University Hospital Johannes Gutenberg Mainz
Languages
English
German
Publications
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
30 August, 2023
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.
27 April, 2023
HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia.
6 April, 2023
Location
Langenbeckstraße, 1, 55131 Mainz, Germany
FAQ
Where does the doctor practice?
What is the specialization of Dr. med. Daniel Sasca?
The primary specialization of the doctor is internal medicine, hematology, oncology, and drug-based tumor therapy.
What is the experience of the specialist?
Dr. med. Daniel Sasca has been practicing for more than 16 years.
Dr. med. Daniel Sasca
Get individual treatment plan and cost estimate. Non-binding 100% free assessment.
© Dr. med. Daniel Sasca